KRAS and ovarian cancer: Upregulation of TNFα signaling via the NFκB pathway in good responders to HIPEC may reflect the increased systemic inflammatory response seen after cisplatin-based HIPEC treatments.24 The second greatest upregulated gene pathway among good responders was the KRAS signaling pathway, a pathway predominantly seen in type II (non-HGS) ovarian cancer tumors.